{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:19Z","timestamp":1792788079496,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82002492"],"award-info":[{"award-number":["82002492"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Natural Science Foundation of Guangxi","award":["2018GXNSFBA281159"],"award-info":[{"award-number":["2018GXNSFBA281159"]}]},{"name":"the Training Program for Excellent Medical Talent of the First Affiliated Hospital of Guangxi Medical University","award":["202207"],"award-info":[{"award-number":["202207"]}],"id":[{"id":"https:\/\/ror.org\/030sc3x20","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Characteristic Innovation Team of the First Affiliated Hospital of Guangxi Medical University","award":["YYZS2022004"],"award-info":[{"award-number":["YYZS2022004"]}],"id":[{"id":"https:\/\/ror.org\/030sc3x20","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the First-class discipline innovation-driven talent program of Guangxi Medical University","id":[{"id":"https:\/\/ror.org\/03dveyr97","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Our preliminary study found that Men1 is an oncogene and a potential therapeutic target in gastric cancer (GC). Chemotherapy remains a common therapeutic regimen for GC, but is frequently limited by multidrug resistance and poor intratumoral coordination of combination drugs. Targeting Menin may enhance chemotherapy sensitivity, but efficient co-delivery of Menin inhibitors and chemotherapeutics is hindered by the profound spatiotemporal pharmacokinetic decoupling of the drugs in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We first evaluated the synergistic antitumor effect and Menin\/p53-associated mechanism of BMF-219 combined with 5-fluorouracil (5-FU) in gastric cancer models. We then engineered a hierarchically assembled, cascade-responsive hyaluronic acid (HA)-decorated liposome\/mesoporous silica nanoplatform (HLM@BF) for coordinated co-delivery of BMF-219 and 5-FU. The system features a glutathione (GSH)-degradable disulfide-bridged mesoporous silica core, cloaked with a pH-sensitive lipid bilayer and decorated with HA for targeting. The synergistic efficacy and biological mechanism were evaluated through bioinformatic analysis, RNA sequencing (RNA-seq), in vitro assays, and in vivo experiments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>BMF-219 sensitized GC cells to 5-FU-induced apoptosis through modulation of Menin- and p53-associated apoptotic signaling. HLM@BF was constructed successfully, and showed colloidal stability in serum-containing medium, pH\/GSH-responsive co-delivery, enhanced CD44-associated uptake, endo\/lysosomal redistribution or escape, increased tumor accumulation, and suppressed xenograft growth with favorable biosafety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HLM@BF integrates Menin inhibition with 5-FU chemotherapy and enhances antitumor efficacy through Menin- and p53-associated apoptotic signaling, providing a targeted nanomedicine strategy for gastric cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03784-6","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:43:12Z","timestamp":1784076192000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cascade-responsive HA-decorated liposome\/mesoporous silica nanoplatform co-delivering BMF-219 and 5-FU enhances gastric cancer chemotherapy through Menin- and p53-associated apoptotic signaling"],"prefix":"10.1186","volume":"45","author":[{"given":"Shanhu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanshuo","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runchuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chhingher","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"16","key":"3784_CR1","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3748\/wjg.v29.i16.2452","volume":"29","author":"WJ Yang","year":"2023","unstructured":"Yang WJ, Zhao HP, Yu Y, et al. Updates on global epidemiology, risk and prognostic factors of gastric cancer . World J Gastroenterol. 2023;29(16):2452\u201368.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"3784_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","volume":"23","author":"JA Ajani","year":"2025","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, et al. Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology . J Natl Compr Canc Netw. 2025;23(5):169\u201391.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"3784_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13046-021-02229-6","volume":"41","author":"S Dong","year":"2022","unstructured":"Dong S, Liang S, Cheng Z, et al. ROS\/PI3K\/Akt and Wnt\/\u03b2-catenin signalings activate HIF-1\u03b1-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer . J Exp Clin Cancer Res. 2022;41(1):15.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3784_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0014-4827(03)00223-4","volume":"289","author":"H Uetsuka","year":"2003","unstructured":"Uetsuka H, Haisa M, Kimura M, et al. Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line . Exp Cell Res. 2003;289(1):27\u201335.","journal-title":"Exp Cell Res"},{"issue":"3","key":"3784_CR5","first-page":"609","volume":"14","author":"N Matsuhashi","year":"2005","unstructured":"Matsuhashi N, Saio M, Matsuo A, et al. The evaluation of gastric cancer sensitivity to 5-FU\/CDDP in terms of induction of apoptosis: time- and p53 expression-dependency of anti-cancer drugs . Oncol Rep. 2005;14(3):609\u201315.","journal-title":"Oncol Rep"},{"issue":"6","key":"3784_CR6","first-page":"1563","volume":"26","author":"N Matsuhashi","year":"2005","unstructured":"Matsuhashi N, Saio M, Matsuo A, et al. Apoptosis induced by 5-fluorouracil, cisplatin and paclitaxel are associated with p53 gene status in gastric cancer cell lines . Int J Oncol. 2005;26(6):1563\u20137.","journal-title":"Int J Oncol"},{"issue":"28","key":"3784_CR7","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1038\/s41388-025-03411-2","volume":"44","author":"H Huang","year":"2025","unstructured":"Huang H, Fang L, Zhu C, et al. YBX1 promotes 5-Fluorouracil resistance in gastric cancer via m5C-dependent ATG9A mRNA stabilization through autophagy . Oncogene. 2025;44(28):2357\u201371.","journal-title":"Oncogene"},{"issue":"9","key":"3784_CR8","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1038\/s41588-024-01874-9","volume":"56","author":"P Su","year":"2024","unstructured":"Su P, Liu Y, Chen T, et al. In vivo CRISPR screens identify a dual function of MEN1 in regulating tumor\u2013microenvironment interactions . Nat Genet. 2024;56(9):1890\u2013902.","journal-title":"Nat Genet"},{"issue":"43","key":"3784_CR9","doi-asserted-by":"publisher","first-page":"17480","DOI":"10.1073\/pnas.1312022110","volume":"110","author":"B Xu","year":"2013","unstructured":"Xu B, Li SH, Zheng R, et al. Menin promotes hepatocellular carcinogenesis and epigenetically up-regulates Yap1 transcription . Proc Natl Acad Sci U S A. 2013;110(43):17480\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3784_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/1535-7163.MCT-17-0580","volume":"17","author":"K Kempinska","year":"2018","unstructured":"Kempinska K, Malik B, Borkin D, et al. Pharmacologic Inhibition of the Menin-MLL Interaction Leads to Transcriptional Repression of PEG10 and Blocks Hepatocellular Carcinoma . Mol Cancer Ther. 2018;17(1):26\u201338.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"3784_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-07539-3","volume":"24","author":"SH Wang","year":"2025","unstructured":"Wang SH, Jiang JX, Zheng KT et al. Exosome-derived Menin from cancer-associated fibroblasts promotes gastric cancer progression by activating the HSPA6\/JNK\/JunD pathway and inducing EMT . J Transl Med. 2025;24(1):274.","journal-title":"J Transl Med"},{"issue":"9","key":"3784_CR12","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.neo.2021.07.008","volume":"23","author":"Y Capodanno","year":"2021","unstructured":"Capodanno Y, Chen Y, Schrader J, et al. Cross-talk among MEN1, p53 and Notch regulates the proliferation of pancreatic neuroendocrine tumor cells by modulating INSM1 expression and subcellular localization . Neoplasia. 2021;23(9):979\u201392.","journal-title":"Neoplasia"},{"issue":"1","key":"3784_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13058-022-01547-7","volume":"24","author":"A Salvati","year":"2022","unstructured":"Salvati A, Melone V, Sellitto A, et al. Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer . Breast Cancer Res. 2022;24(1):52.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"3784_CR14","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1038\/s41598-025-34922-3","volume":"16","author":"T Yamamoto-Fukuda","year":"2026","unstructured":"Yamamoto-Fukuda T, Akiyama N, Kojima H. Menin-MLL inhibitors as a new therapeutic target for middle ear cholesteatoma . Sci Rep. 2026;16(1):2539.","journal-title":"Sci Rep"},{"issue":"4","key":"3784_CR15","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3324\/haematol.2024.286537","volume":"110","author":"HE Carraway","year":"2025","unstructured":"Carraway HE, Nakitandwe J, Cacovean A, et al. Complete remission of NUP98 fusion-positive acute myeloid leukemia with the covalent menin inhibitor BMF-219, icovamenib . Haematologica. 2025;110(4):1041\u20136.","journal-title":"Haematologica"},{"issue":"1","key":"3784_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-024-01632-8","volume":"17","author":"KVG Nadiminti","year":"2024","unstructured":"Nadiminti KVG, Sahasrabudhe KD, Liu H. Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead . J Hematol Oncol. 2024;17(1):113.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3784_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41698-025-00926-5","volume":"9","author":"H Deng","year":"2025","unstructured":"Deng H, Wang Y, Xiao L, et al. SHMT inhibitor synergizes with 5-Fu to suppress gastric cancer via cell cycle arrest and chemoresistance alleviation . NPJ Precis Oncol. 2025;9(1):135.","journal-title":"NPJ Precis Oncol"},{"issue":"7","key":"3784_CR18","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1158\/1535-7163.MCT-06-0118","volume":"5","author":"LD Mayer","year":"2006","unstructured":"Mayer LD, Harasym TO, Tardi PG, et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice . Mol Cancer Ther. 2006;5(7):1854\u201363.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"3784_CR19","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.7150\/thno.38287","volume":"10","author":"J Sun","year":"2020","unstructured":"Sun J, Chen Y, Xu J, et al. High Loading of Hydrophobic and Hydrophilic Agents via Small Immunostimulatory Carrier for Enhanced Tumor Penetration and Combinational Therapy . Theranostics. 2020;10(3):1136\u201350.","journal-title":"Theranostics"},{"issue":"11","key":"3784_CR20","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1158\/1078-0432.CCR-03-0655","volume":"10","author":"TY Kim","year":"2004","unstructured":"Kim TY, Kim DW, Chung JY, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies . Clin Cancer Res. 2004;10(11):3708\u201316.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3784_CR21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"20","author":"S Zheng","year":"2022","unstructured":"Zheng S, Wang W, Aldahdooh J, et al. SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets . Genomics Proteom Bioinf. 2022;20(3):587\u201396.","journal-title":"Genomics Proteom Bioinf"},{"issue":"W1","key":"3784_CR22","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples . Nucleic Acids Res. 2022;50(W1):W739\u201343.","journal-title":"Nucleic Acids Res"},{"issue":"13","key":"3784_CR23","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1158\/0008-5472.CAN-22-3599","volume":"83","author":"J Xu","year":"2023","unstructured":"Xu J, Ye Z, Zhuo Q, et al. MEN1 Degradation Induced by Neddylation and the CUL4B-DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression . Cancer Res. 2023;83(13):2226\u201347.","journal-title":"Cancer Res"},{"issue":"9","key":"3784_CR24","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1158\/0008-5472.CAN-18-2133","volume":"79","author":"BW Katona","year":"2019","unstructured":"Katona BW, Glynn RA, Paulosky KE, et al. Combined Menin and EGFR Inhibitors Synergize to Suppress Colorectal Cancer via EGFR-Independent and Calcium-Mediated Repression of SKP2 Transcription . Cancer Res. 2019;79(9):2195\u2013207.","journal-title":"Cancer Res"},{"issue":"1","key":"3784_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-026-04314-2","volume":"26","author":"JX Jiang","year":"2026","unstructured":"Jiang JX, Zhang SJ, Zhao K et al. Hsa-miR-149-5p targets Men1 to inhibit the progression of gastric cancer through the HSPA6\/JNK pathway . Cancer Cell Int. 2026;26(1):254.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"3784_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3892\/br.2023.1609","volume":"18","author":"F Ren","year":"2023","unstructured":"Ren F, Guo Q, Zhou H. Menin represses the proliferation of gastric cancer cells by interacting with IQGAP1 . Biomed Rep. 2023;18(4):27.","journal-title":"Biomed Rep"},{"key":"3784_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.biopha.2017.04.059","volume":"92","author":"GY Xu","year":"2017","unstructured":"Xu GY, Tang XJ. Troxerutin (TXN) potentiated 5-Fluorouracil (5-Fu) treatment of human gastric cancer through suppressing STAT3\/NF-\u03baB and Bcl-2 signaling pathways . Biomed Pharmacother. 2017;92:95\u2013107.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"3784_CR28","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1042\/BST20210750","volume":"49","author":"WD Fairlie","year":"2021","unstructured":"Fairlie WD, Lee EF. Targeting the BCL-2-regulated apoptotic pathway for the treatment of solid cancers . Biochem Soc Trans. 2021;49(5):2397\u2013410.","journal-title":"Biochem Soc Trans"},{"key":"3784_CR29","doi-asserted-by":"crossref","unstructured":"Ramesh P, Medema JP. BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy . Apoptosis. 2020;25(5\u20136):305\u2009\u2013\u200920.","DOI":"10.1007\/s10495-020-01601-9"},{"issue":"1","key":"3784_CR30","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41392-023-01536-y","volume":"8","author":"D Fan","year":"2023","unstructured":"Fan D, Cao Y, Cao M, et al. Nanomedicine in cancer therapy . Signal Transduct Target Ther. 2023;8(1):293.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"3784_CR31","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/s41565-025-01932-1","volume":"20","author":"K Benderski","year":"2025","unstructured":"Benderski K, Lammers T, Sofias AM. Analysis of multi-drug cancer nanomedicine . Nat Nanotechnol. 2025;20(8):1163\u201372.","journal-title":"Nat Nanotechnol"},{"issue":"11","key":"3784_CR32","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/s41565-024-01754-7","volume":"19","author":"P Joyce","year":"2024","unstructured":"Joyce P, Allen CJ, Alonso MJ, et al. A translational framework to DELIVER nanomedicines to the clinic . Nat Nanotechnol. 2024;19(11):1597\u2013611.","journal-title":"Nat Nanotechnol"},{"issue":"5","key":"3784_CR33","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1039\/C8BM01669K","volume":"7","author":"L Shen","year":"2019","unstructured":"Shen L, Pan S, Niu D, et al. Facile synthesis of organosilica-capped mesoporous silica nanocarriers with selective redox-triggered drug release properties for safe tumor chemotherapy . Biomater Sci. 2019;7(5):1825\u201332.","journal-title":"Biomater Sci"},{"issue":"40","key":"3784_CR34","doi-asserted-by":"publisher","first-page":"7009","DOI":"10.1039\/C4TB01030B","volume":"2","author":"SR Gayam","year":"2014","unstructured":"Gayam SR, Wu SP. Redox responsive Pd(ii) templated rotaxane nanovalve capped mesoporous silica nanoparticles: a folic acid mediated biocompatible cancer-targeted drug delivery system . J Mater Chem B. 2014;2(40):7009\u201316.","journal-title":"J Mater Chem B"},{"issue":"7","key":"3784_CR35","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1039\/D1BM00015B","volume":"9","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Jiao X, Wang Z, et al. Biphasic synthesis of biodegradable urchin-like mesoporous organosilica nanoparticles for enhanced cellular internalization and precision cascaded therapy . Biomater Sci. 2021;9(7):2584\u201397.","journal-title":"Biomater Sci"},{"issue":"1","key":"3784_CR36","first-page":"36","volume":"17","author":"SS Agrawal","year":"2024","unstructured":"Agrawal SS, Baliga V, Londhe VY. Liposomal Formulations: Recent Update Pharm. 2024;17(1):36.","journal-title":"Liposomal Formulations: Recent Update Pharm"},{"issue":"6","key":"3784_CR37","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1021\/acsmaterialsau.3c00032","volume":"3","author":"M Mehta","year":"2023","unstructured":"Mehta M, Bui TA, Yang X, et al. Lipid-Based Nanoparticles for Drug\/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development . ACS Mater Au. 2023;3(6):600\u201319.","journal-title":"ACS Mater Au"},{"issue":"1","key":"3784_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0005-2736(01)00389-3","volume":"1515","author":"S Sim\u00f5es","year":"2001","unstructured":"Sim\u00f5es S, Slepushkin V, D\u00fczg\u00fcnes N, et al. On the mechanisms of internalization and intracellular delivery mediated by pH-sensitive liposomes . Biochim Biophys Acta. 2001;1515(1):23\u201337.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"3784_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15030915","volume":"15","author":"TS Moreira","year":"2023","unstructured":"Moreira TDS, Silva ADO, Vasconcelos BRF et al. DOPE\/CHEMS-Based EGFR-Targeted Immunoliposomes for Docetaxel Delivery: Formulation Development, Physicochemical Characterization and Biological Evaluation on Prostate Cancer Cells . Pharmaceutics. 2023;15(3):915.","journal-title":"Pharmaceutics"},{"issue":"1","key":"3784_CR40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41467-023-44572-6","volume":"15","author":"Z Luo","year":"2024","unstructured":"Luo Z, Huang Y, Batra N, et al. Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy . Nat Commun. 2024;15(1):255.","journal-title":"Nat Commun"},{"issue":"Pt 1","key":"3784_CR41","doi-asserted-by":"publisher","first-page":"130856","DOI":"10.1016\/j.ijbiomac.2024.130856","volume":"265","author":"L Shanmugam","year":"2024","unstructured":"Shanmugam L, Venkatasubbu GD, Jayaraman M. Hyaluronan-based nano-formulation with mesoporous silica enhances the anticancer efficacy of phloroglucinol against gastrointestinal cancers . Int J Biol Macromol. 2024;265(Pt 1):130856.","journal-title":"Int J Biol Macromol"},{"key":"3784_CR42","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.2147\/IJN.S213974","volume":"14","author":"Z Fang","year":"2019","unstructured":"Fang Z, Li X, Xu Z, et al. Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe(3)O(4) nanoparticles for targeted drug delivery . Int J Nanomed. 2019;14:5785\u201397.","journal-title":"Int J Nanomed"},{"key":"3784_CR43","doi-asserted-by":"publisher","first-page":"8949","DOI":"10.2147\/IJN.S472276","volume":"19","author":"Y Yang","year":"2024","unstructured":"Yang Y, Yang S, Zhang B, et al. Hybrid Liposome-MSN System with Co-Delivering Potential Effective Against Multidrug-Resistant Tumor Targets in Mice Model . Int J Nanomed. 2024;19:8949\u201370.","journal-title":"Int J Nanomed"},{"issue":"1","key":"3784_CR44","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1038\/s41467-023-37465-1","volume":"14","author":"LN Kasiewicz","year":"2023","unstructured":"Kasiewicz LN, Biswas S, Beach A, et al. GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy . Nat Commun. 2023;14(1):2776.","journal-title":"Nat Commun"},{"issue":"13","key":"3784_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/polym14132601","volume":"14","author":"V Ejigah","year":"2022","unstructured":"Ejigah V, Owoseni O, Bataille-Backer P et al. Approaches to Improve Macromolecule and Nanoparticle Accumulation in the Tumor Microenvironment by the Enhanced Permeability and Retention Effect . Polym (Basel). 2022;14(13):2601.","journal-title":"Polymers"},{"issue":"1","key":"3784_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12575-020-00137-1","volume":"23","author":"W Kang","year":"2021","unstructured":"Kang W, Maher L, Michaud M, et al. Development of a Novel Orthotopic Gastric Cancer Mouse Model . Biol Proced Online. 2021;23(1):1.","journal-title":"Biol Proced Online"},{"key":"3784_CR47","doi-asserted-by":"publisher","first-page":"1753215","DOI":"10.3389\/fimmu.2026.1753215","volume":"17","author":"L Liang","year":"2026","unstructured":"Liang L, Wang W. The impact of p53 mutation on tumor immune evasion: mechanistic insights and clinical implications . Front Immunol. 2026;17:1753215.","journal-title":"Front Immunol"},{"issue":"11","key":"3784_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17111942","volume":"17","author":"Y Cui","year":"2016","unstructured":"Cui Y, Guo G. Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment . Int J Mol Sci. 2016;17(11):1942.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"3784_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/cells11213434","volume":"11","author":"SS Kim","year":"2022","unstructured":"Kim SS, Harford JB, Moghe M et al. A Novel P53 Nanomedicine Reduces Immunosuppression and Augments Anti-PD-1 Therapy for Non-Small Cell Lung Cancer in Syngeneic Mouse Models . Cells. 2022;11(21):3434.","journal-title":"Cells"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03784-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03784-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03784-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:03:47Z","timestamp":1791475427000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03784-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3784"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03784-6","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University. Institutional review board approval was obtained, and all the animal experiments were performed in accordance with the institutional guidelines of the Institutional Animal Care and Use Committee of the First Affiliated Hospital of Guangxi Medical University, Nanning, China.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors consent to publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"210"}}